Open Access<p>Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease</p>
Author(s) -
Robert Burkes,
Ralph J. Panos
Publication year - 2020
Publication title -
journal of experimental pharmacology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.555
H-Index - 12
ISSN - 1179-1454
DOI - 10.2147/jep.s259328
Subject(s) - indacaterol , medicine , copd , agonist , bronchodilator , clinical trial , bronchospasm , asthma , pharmacology , intensive care medicine , receptor
Inhaled β-agonists have been foundational medications for maintenance COPD management for decades. Through activation of cyclic adenosine monophosphate pathways, these agents relax airway smooth muscle and improve expiratory airflow by relieving bronchospasm and alleviating air trapping and dynamic hyperinflation improving breathlessness, exertional capabilities, and quality of life. β-agonist drug development has discovered drugs with increasing longer durations of action: short acting (SABA) (4-6 h), long acting (LABA) (6-12 h), and ultra-long acting (ULABA) (24 h). Three ULABAs, indacaterol, olodaterol, and vilanterol, are approved for clinical treatment of COPD.